Amalgamated Bank grew its position in United Therapeutics Co. (NASDAQ:UTHR) by 6.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,685 shares of the biotechnology company’s stock after purchasing an additional 489 shares during the period. Amalgamated Bank’s holdings in United Therapeutics were worth $1,285,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Quantbot Technologies LP raised its holdings in United Therapeutics by 537.3% in the third quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 822 shares during the period. SeaCrest Wealth Management LLC acquired a new stake in United Therapeutics in the fourth quarter worth $178,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in United Therapeutics in the third quarter worth $156,000. HL Financial Services LLC acquired a new stake in United Therapeutics in the fourth quarter worth $217,000. Finally, CIBC Asset Management Inc acquired a new stake in United Therapeutics in the fourth quarter worth $220,000.
Shares of United Therapeutics Co. (UTHR) opened at $116.07 on Tuesday. United Therapeutics Co. has a twelve month low of $107.82 and a twelve month high of $152.55. The company has a current ratio of 3.26, a quick ratio of 3.01 and a debt-to-equity ratio of 0.12. The company has a market cap of $5,020.00, a price-to-earnings ratio of 10.60 and a beta of 1.32.
A number of equities research analysts recently commented on UTHR shares. Barclays restated an “underweight” rating and set a $105.00 price objective (down from $115.00) on shares of United Therapeutics in a report on Thursday, February 22nd. Credit Suisse Group restated an “underperform” rating and set a $115.00 price objective (down from $120.00) on shares of United Therapeutics in a report on Thursday, February 22nd. ValuEngine lowered shares of United Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. TheStreet upgraded shares of United Therapeutics from a “c+” rating to a “b” rating in a report on Friday, December 15th. Finally, BidaskClub lowered shares of United Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, February 24th. Five investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. United Therapeutics has an average rating of “Hold” and a consensus target price of $135.20.
COPYRIGHT VIOLATION NOTICE: “Amalgamated Bank Has $1.29 Million Holdings in United Therapeutics Co. (UTHR)” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3258665/amalgamated-bank-has-1-29-million-holdings-in-united-therapeutics-co-uthr.html.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.